Short Interest in Hill-Rom Holdings, Inc. (NYSE:HRC) Rises By 8.1%

Hill-Rom Holdings, Inc. (NYSE:HRC) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 2,000,000 shares, a growth of 8.1% from the September 30th total of 1,850,000 shares. Approximately 3.0% of the company’s stock are sold short. Based on an average trading volume of 411,900 shares, the short-interest ratio is currently 4.9 days.

In other Hill-Rom news, SVP Deborah Rasin sold 4,739 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $103.97, for a total transaction of $492,713.83. Following the completion of the transaction, the senior vice president now owns 31,001 shares in the company, valued at approximately $3,223,173.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.73% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. United Services Automobile Association boosted its stake in Hill-Rom by 0.6% during the 2nd quarter. United Services Automobile Association now owns 21,608 shares of the medical technology company’s stock worth $2,261,000 after purchasing an additional 132 shares during the period. Whittier Trust Co. boosted its stake in Hill-Rom by 29.8% during the 3rd quarter. Whittier Trust Co. now owns 649 shares of the medical technology company’s stock worth $68,000 after purchasing an additional 149 shares during the period. Texas Permanent School Fund boosted its stake in Hill-Rom by 0.4% during the 3rd quarter. Texas Permanent School Fund now owns 45,477 shares of the medical technology company’s stock worth $4,786,000 after purchasing an additional 160 shares during the period. Bay Harbor Wealth Management LLC boosted its stake in Hill-Rom by 31.8% during the 3rd quarter. Bay Harbor Wealth Management LLC now owns 705 shares of the medical technology company’s stock worth $72,000 after purchasing an additional 170 shares during the period. Finally, Flagship Harbor Advisors LLC boosted its stake in Hill-Rom by 8.4% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 2,254 shares of the medical technology company’s stock worth $237,000 after purchasing an additional 174 shares during the period. Hedge funds and other institutional investors own 82.63% of the company’s stock.

Shares of Hill-Rom stock opened at $104.98 on Monday. The company has a fifty day simple moving average of $102.53 and a 200-day simple moving average of $103.28. Hill-Rom has a 12-month low of $81.85 and a 12-month high of $111.63. The company has a current ratio of 1.31, a quick ratio of 1.10 and a debt-to-equity ratio of 1.13. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 1.77 and a beta of 0.83.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, November 1st. The medical technology company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.04. Hill-Rom had a net margin of 5.24% and a return on equity of 21.67%. The business had revenue of $782.80 million during the quarter, compared to analysts’ expectations of $759.14 million. During the same quarter in the prior year, the business posted $1.63 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, analysts forecast that Hill-Rom will post 5.52 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 16th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Friday, December 13th. Hill-Rom’s dividend payout ratio is currently 16.54%.

Several research analysts have recently issued reports on the stock. KeyCorp upped their target price on shares of Hill-Rom from $114.00 to $125.00 and gave the company an “overweight” rating in a report on Monday, August 5th. UBS Group upped their target price on shares of Hill-Rom from $122.00 to $130.00 and gave the company a “buy” rating in a report on Monday, November 4th. Needham & Company LLC restated a “buy” rating and issued a $125.00 target price on shares of Hill-Rom in a report on Tuesday, August 6th. Morgan Stanley upped their target price on shares of Hill-Rom from $108.00 to $113.00 and gave the company an “equal weight” rating in a report on Monday, November 4th. Finally, Barclays upped their target price on shares of Hill-Rom from $108.00 to $116.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $118.67.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Recommended Story: Penny Stocks, Risk and Reward Factors

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.